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Studies of macrophage therapy for cirrhosis – from mice to men 
We read with interest the recently published paper by Ma et al. (1) in which they 
examined the effects of macrophage infusion in experimental liver fibrosis. The beneficial 
effects on measures of liver scarring and regeneration following the delivery of bone 
marrow derived macrophages (BMDMs) suggest clinical potential. 
BMDMs injected during iterative liver injury resulted in the hepatic engraftment of 
relatively few donor cells. Consistent with our previously reported findings (2), 
macrophage administration resulted in modulation of the host immune response with 
upregulation of antifibrotic matrix metalloproteinases, apoptosis of scar producing 
myofibroblasts and subsequent reduction in liver fibrosis. The injection of unpolarized 
(naïve) BMDMs mediated these effects as did those previously stimulated in vitro to a 
classical "M1" phenotype. In contrast, BMDMs activated to the alternative "M2" 
phenotype were not beneficial. 
Our group's work characterizing the "restorative macrophage" during the spontaneous 
regression of fibrosis after liver injury, has shown that these phagocytic Ly6Clo cells do 
not conform to the traditional M1-M2 paradigm (3). The hepatic macrophage population 
extracted from recipient liver after BMDM therapy in this paper appeared to have a 
comparable phenotype. This could indicate that BMDM therapy is able to harness this 
endogenous repair process, critically, in the context of ongoing liver injury. The 
demonstrated upregulation of macrophage chemokines (CCL-2 and -3) is consistent with 
the hepatic recruitment of host cells. Amplification of the effects of the initial cell 
injection through paracrine signaling is an attractive concept to explain the enduring 
changes found weeks after BMDM delivery. However, this does not exclude a significant 
contribution to the increased numbers of hepatic F4/80+ macrophages from proliferation 
of resident hepatic macrophages in addition to recruitment (4). 
Ma et al. (1) also demonstrated that BMDM infusion increased the number of activated 
hepatic NK cells, with the potential to promote myofibroblast apoptosis. Whether this NK 
cell enrichment reflects a direct effect of the infused BMDMs or a consequence of the 
modulation in host macrophage phenotype remains to be elucidated. Further studies, 
administering BMDMs deficient in specific chemokines could provide further mechanistic 
insights. 
We have reported increased serum albumin levels following BMDM therapy (2). This 
finding has also been recapitulated by Ma et al. (1). The increase in Ki67+ hepatocytes 
identifies hepatocyte proliferation as a regenerative mechanism after BMDM delivery. 
Our work exploring BMDM therapy mediated regeneration in both the injured (2) and 
uninjured (5) liver has also indicated a role for the liver progenitor cell (LPC) mitogen 
TWEAK. This cytokine specifically activates the LPC compartment thereby increasing liver 
cell mass. Evaluation of this axis following injection of differentially polarized 
macrophages would be informative from biological and translational perspectives. 
The authors also tested BMDM therapy in cholestatic fibrosis due to bile duct ligation. 
The antifibrotic effect was found to be of a similar magnitude to that detected in the 
carbon tetrachloride (CCl4) induced model of hepatitic injury. The mechanistic studies 
reported in this article were carried out exclusively in the CCl4 model. We have 
previously demonstrated fundamental differences in the spatial and in turn functional 
characteristics of biliary versus hepatitic fibrosis and regeneration (6). Therefore, further 
exploration of the processes underlying the effects observed in this cholestatic model will 
be of great interest. 
  
Following our initial report (2), we have sought to test the translational potential of 
BMDM therapy. Human macrophages injected into mice with experimental liver fibrosis 
showed similar positive effects on liver fibrosis and function (7). Building on this 
infrastructure, our group has validated and scaled-up a Good Manufacturing Practice-
compliant process for deriving human macrophages for therapy (8). A first in man study 
of autologous macrophage infusion in cirrhosis (ISRCTN 10368050) has already 
commenced to determine whether these promising pre-clinical findings can yield 
effective treatment for patients with cirrhosis. 
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